homepage-top-section

The regulator has accepted the company’ new drug application (NDA) for the combination therapy and as continuation of quizartinib monotherapy after consolidation to treat FLT3-ITD­–positive AML patients. Quizartinib,

If approved by the regulatory agency, neffy would be the first non-injectable treatment available to patients suffering with allergic reactions of Type I, including anaphylaxis. The regulatory body has

The platform of Refuge is a synthetic biology system leveraging an expression modulation strategy to repress or activate transcription of target genes. Early pre-clinical data indicate a potential

The regulator has recommended the radioligand therapy along with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition to treat progressive PSMA- positive mCRPC adult

The companies will assess AdAlta’s CXCR4 inhibiting i-bodies as cancer therapeutics, using GPCR’s combination inhibition technique. AdAlta owns an i-bodies panel that inhibit CXCR4 signalling in different ways.

The company is seeking regulatory approval for SIS-101-ADO to treat Autosomal Dominant Osteopetrosis Type 2 (ADO2) patients. CSSi LifeSciences will be responsible for coordinating the regulatory process that

The CRISPR-based gene therapy has been indicated to treat Shiga-toxin producing bacterial infection to prevent hemolytic uremic syndrome (HUS). It has been designed to target Shiga toxins from

The injection (abbreviated as relma-cel ) has been approved to treat adult patients with follicular lymphoma that relapses or is refractory in 24 months of second-line or above

Discovered and developed by Lilly, Cyramza has been approved for the treatment of HCC patients with an alpha fetoprotein of ≥400 ng/mL and who have received treatment with